P3-238: imr-assayed plasma aβ42 and t-tau classified mild cognitive impaired and mild alzheimer's disease subjects with high accuracies in a multi-country cross-sectional study
Lih-Fen Lue,Ming-Chyi Pai,Ta-Fu Chen,Chaur-Jong Hu,Li-Kai Huang,Wei-Che Lin,Chau-Chung Wu,Sui-Hing Yan,Pei-Ning Wang,Hiroyuki Hatsuta,Yoshiaki Itoh,Satoru Morimoto,Akitoshi Takeda,Jun Liu,Haiqun Xie,Jian-shing Jeng,Marwan N. Sabbagh,Kaj Blennow,Shieh-Yueh Yang,Ming-Jang Chiu
DOI: https://doi.org/10.1016/j.jalz.2019.06.3268
2019-01-01
Abstract:Aβ and Tau are the most intensively investigated plasma biomarkers which may play strategic roles in identifying subjects suitable for enrolling in expensive brain amyloid or tau imaging in clinical trials. Currently, the progress in establishing their utility potentials has been accelerated by new approaches and technologies that have superior technical sensitivity and accuracy of the measurement. We have been investigating one of these new technologies called ImmunoMagnetic Reduction (IMR). Here, we report the findings from a multi-country study that validated the accuracies of IMR-assayed plasma Aβ42 and total-Tau (t-Tau) in identifying subjects at mild cognitive impairment (MCI) and mild Alzheimer's disease (AD) stages. Enrolled participants included 337 normal control (NC), 57 MCI, and 165 mild AD from China, Japan, Sweden, Taiwan, and U.S. during 2014-2017. The clinical assessment by experienced neurologists at respective participating sites followed NIA-AA criteria. IMR assays were performed with demographic and diagnosis information deidentified. The results were analyzed for discriminatory accuracies between NC, MCI, and mild AD or between NC and MCI and mild AD combined by Receiver Operating Characteristics Area Under Curves (AUCs). The means ± standard errors of age were 66.1±1.5, 71.9±1.3, and 75.5±0.8 respectively for NC, MCI, and mild AD. The levels of Aβ42 and t-Tau were significantly different between groups; highest in mild AD and lowest in NC group. The composite marker defined by the product of Aβ42 and t-Tau levels differed significantly between all paired comparisons. The AUCs of Aβ42 and t-Tau as single markers were 0.88−0.92 (P < .001) and 0.90−0.93 (P < .001) as composite marker when using for discriminating NC from MCI, AD, or MCI and AD combined. The cut-off value at 453.13 (pg/ml)2 achieved > 0.90 discriminatory accuracies between groups. The findings validated that plasma Aβ42 and t-Tau measured by IMR assays had high accuracy for distinguishing NC from MCI and mild AD. Further studies to establish their utilities as pre-clinical screening or clinical diagnosis tests are warranted.